

Ludwig Scientist (s)	Affiliation (s)	Session Time	Location	Session Type	Session Title	Presentation/Abstract Title & Time		
SATURDAY, APRIL 16								
Crystal Mackall	Ludwig Stanford	8:00am - 10:00am	Room 288, Morial Convention Center	Educational Session	Using Tumor Biology to Drive More Effective Sarcoma Therapy	9:30am - 9:55am: Immunotherapies for Sarcoma: Progress and Challenges		
Crystal Mackall	Ludwig Stanford	10:15am -12:15pm	Room 278, Morial Convention Center	Educational Session	Cancer Immunology for the Non-Immunologist: Tutorial	10:15am - 12:15pm: Education Manuscript		
			SUNDAY, APR	IL 17				
George Coukos	Ludwig Lausanne	7:00am - 8:00am	Room 343, Morial Convention Center	Meet-the-Expert Session	Ovarian cancer immunotherapy. From bench to bedside	Invited speaker		
Xin Lu	Ludwig Oxford	7:00am - 8:00am	Room 288, Morial Convention Center	Meet-the-Expert Session	Cellular Plasticity, Cellular Heterogeneity and Single Cell Sequencing	Invited speaker		
David Lane	Ludwig New York	7:00am - 8:00am	Room 357, Morial Convention Center	Meet-the-Expert Session	Stapled Peptides as a New Form of Medicine for Oncology Targets: Challenges and Progress	Invited speaker		
Matthew Vander Heiden	Ludwig MIT	7:00am - 8:00am	Room 271, Morial Convention Center	Meet-the-Expert Session	The Role of Metabolism in Supporting Tumor Growth	Invited speaker		
Bob Weinberg	Ludwig MIT	8:15am - 9:00am	Hall F, Morial Convention Center	Awards and Lectures	Thirteenth Annual AACR Award for Lifetime Achievement in Cancer Research	Award recipient		
Franziska Michor	Ludwig Harvard	1:00pm - 2:00pm	New Orleans Theater A, Morial Convention Center	Awards and Lectures	Thirty-Sixth Annual AACR Award for Outstanding Achievement in Cancer Research	Award recipient. Presentation title: Biology and dynamics of cancer evolution		
Olivier De Henau,* Taha Merghoub, Jedd Wolchok	Ludwig MSK	1:00pm - 5:00pm	Section 26, poster board 15	Poster Session	Immune Modulating Agents 1	Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models		
Tyler Jacks**	Ludwig MIT	1:00pm - 5:00pm	Section 30, poster board 8	Poster Session	Mechanisms of Tumorigenesis in Animal Models of Cancer 1	Novel refinements for the autochthonous mouse model of cancer		

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Ming Zhang, Nicholas Roberts, Christine Joseph, Maria Popoli,Kenneth Kinzler, Bert Vogelstein, Nickolas Papadopoulos**	Ludwig Johns Hopkins	1:00pm - 5:00pm	Section 5, poster board 11	Poster Session	Genomic Profiling of Cancers	The genomic landscapes of inflammatory bowel disease-associated colorectal cancers
Anthony Letai**	Ludwig Harvard	1:00pm - 5:00pm	Section 20, poster board 24	Poster Session	Biomarkers	Mitochondrial perturbations as a novel approach to personalized medicine
Crystal Mackall**	Ludwig Stanford	1:00pm - 5:00pm	Section 27, poster board 2	Poster Session	Therapeutic Antibodies	Pregnancy associated plasma protein A (PAPP-A) is a potential novel therapeutic target in Ewing sarcoma
Fernanda Koyama*, Anamaria Camargo**	Ludwig Sao Paulo	1:00pm - 5:00pm	Section 19, poster board 22	Poster Session	PI3K/AKT Inhibitors	Implications of Akt inhibition for neoadjuvant radiotherapy: improving the rectal cancer treatment
Matthias Ernst*	Ludwig Melbourne	1:00pm - 5:00pm	Section 25, poster board 13	Poster Session	Genetic Determinants and Regulators of Cancer Immunity	Excessive HCK kinase activity in the tumor stroma promotes colorectal cancer progression
Luis Diaz	Ludwig Johns Hopkins	1:00pm - 5:00pm	Section 25, poster board 5	Poster Session	Genetic Determinants and Regulators of Cancer Immunity	Identify and prioritize candidate neoantigens from cancer exome sequencing with unmatched accuracy
Olivier De Henau,* Taha Merghoub, Jedd Wolchok	Ludwig MSK	1:00pm - 5:00pm	Section 26, poster board 15	Poster Session	Immune Modulating Agents 1	Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models
Pierre van der Bruggen	Ludwig Brussels	2:15pm - 4:15pm	La Nouvelle Orleans Ballroom, Morial Convention Center	Clinical Trials Plenary Session	Immuno-oncology Clinical Trials I	3:15pm - 3:35pm: A phase I study of an HLA- DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Irv Weissman	Ludwig Stanford	2:15pm - 4:00pm	Room 393, Morial Convention Center	Major Symposium	AACR-Bayard D. Clarkson Symposium: Tumor Cell of Origin and Cancer Stem Cells	2:55pm - 3:20pm: Normal and neoplastic stem cells
Stephen Hodi*	Ludwig Harvard	2:15pm - 4:15pm	La Nouvelle Orleans Ballroom, Morial Convention Center	Clinical Trials Plenary Session	Immuno-oncology Clinical Trials I	2:00pm - 4:15pm: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
Michael Postow,* Jedd Wolchok, Stephen Hodi**	Ludwig MSK; Ludwig Harvard	2:15pm - 4:15pm	La Nouvelle Orleans Ballroom, Morial Convention Center	Clinical Trials Plenary Session	Immuno-oncology Clinical Trials I	2:00pm - 4:15pm: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Johanna Joyce	Ludwig Lausanne	2:15pm - 4:00pm	Room 293, Morial Convention Center	Major Symposium	Inflammation and Cancer: Targeting the Myeloid Microenvironment	2:55pm - 3:20pm: Deciphering mechanisms of resistance to macrophage-targeted therapies

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Karen Chichowski (Chairperson)	Ludwig Harvard	2:15pm - 4:00pm	New Orleans Theater A, Morial Convention Center	Major Symposium	Epigenetics and Signaling in Cancer	2:55pm - 3:20pm: Co-targeting epigenetic regulators and oncogenic signaling pathways in cancer
Philip Beachy	Ludwig Stanford	2:15pm - 4:00pm	Room 288, Morial Convention Center	Major Symposium	Developmental Pathways	2:25pm - 2:50pm: Stem cells and signaling pathways in regeneration and malignancy
Cigall Kadoch**	Ludwig Harvard	4:15pm - 6:15pm	Room 343, Morial Convention Center	Minisymposium	Disordered Gene Regulation and Chromatin State in Malignant Transformation	4:35pm - 4:50pm: TMPRSS2-ERG drives global mistargeting of mammalian SWI/SNF (BAF) complexes in prostate cancer
Joao Incio,* Keehoon Jung, Dai Fukumura, Rakesh Jain**	Ludwig Harvard	4:15pm - 6:15pm	Room 288, Morial Convention Center	Minisymposium	Highlights in Cancer Prevention Advances	5:05pm - 5:20pm: Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy
Johanna Joyce	Ludwig Lausanne	6:00pm - 8:00pm	Mardi Gras Ballroom D-E, New Orleans Marriott	Town Meeting	Tumor Microenvironment Working Group (TME) Town Hall Meeting and Reception	6:15pm - 6:30pm - Chariperson elect: Remarks; 7:30pm - 7:35pm - Closing Remarks
Crystal Mackall	Ludwig Stanford	6:30pm - 9:30pm	Grand Salon B, Hilton New Orleans Riverside	Town Meeting	AACR Pediatric Cancer Working Group Town Hall Meeting and Networking Reception	6:40pm - 7:30pm: Panelist
			MONDAY, APR	RIL 18		
Ya-Fang Chang,* Yuhao Wang, Geoffrey Greene**	Ludwig Chicago	8:00am - 12:00pm	Section 17, poster board 13	Poster Session	Novel Molecular Targets	Targeting nuclear receptors and their coregulators in triple-negative breast cancer
	Mersana Therapeutics: research conducted with Ludwig licensed technology	8:00am -12:00pm	Section 15, poster board 3	Poster Session	Growth Factor Receptors and Surface Antigens as Therapeutic Targets	Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models
Stephen Hodi	Ludwig Harvard	8:00am -12:00pm	Section 13	Poster Session	Phase I Clinical Trials in Progress	A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)
Surojit Sur,* Yuan Qiao, Anja Fries, Kenneth Kinzler, Bert Vogelstein, Shibin Zhou**	Ludwig Johns Hopkins	8:00am - 12:00pm	Section 19, poster board 30	Poster Session	Drug Delivery 1	PRINT: A protein bioconjugation method with exquisite N-terminal specificity
Surojit Sur,* Kenneth Kinzler, Bert Vogelstein, Shibin Zhou**	Ludwig Johns Hopkins	8:00am - 12:00pm	Section 19, poster board 30	Poster Session	Drug Delivery 1	PRINT: A protein bioconjugation method with exquisite N-terminal specificity

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Ravindra Majeti	Ludwig Stanford	8:00am - 12:00pm	Section 14, poster board 7	Poster Session	Differentiation Therapy	Discovery of new AML and MDS patient subsets sensitive to the highly selective RARα agonist SY-1425 (tamibarotene) through super-enhancer analysis
Matthias Ernst	Ludwig Melbourne	8:00am - 12:00pm	Section 24, poster board 4	Poster Session	Immune Microenvironment and Antitumor Immunity	IL-18 is associated with the onset and progression of gastric cancer
Ash Alizadeh	Ludwig Stanford	10:30am - 12:15pm	Room 288, Morial Convention Center	Recent Advances in Organ Site Research	Genomic Insights Into Lymphoma Pathogenesis, Diagnosis, and Treatment	11:30am -11:55am: Noninvasive lymphoma genotyping and personalized monitoring using circulating DNA
Jedd Wolchok	Ludwig MSK	10:30am - 12:15pm	New Orleans Theater C, Morial Convention Center	Major Symposium	SY35. Addressing the Mechanisms of Resistance and Lack of Response in Cancer Immunotherapy	11:10am -11:35am: Combinations using checkpoint blockade as one means to address resistance
Crystal Mackall**	Ludwig Stanford	1:00pm - 5:00pm	Section 25, poster board 16	Poster Session	Adoptive Cell Therapy	Attenuated oncolytic virus HSV1716 increases in vivo expansion of GD2- targeting CAR T cells in murine solid tumor models
Jedd Wolchok	Ludwig MSK	1:00pm - 5:00pm	Section 27, poster board 21	Poster Session	Therapeutic Antibodies and Vaccines	Pilot study of DNA microseeding to activate immune rejection of canine melanoma
Bert Vogelstein	Ludwig Johns Hopkins	1:00pm - 5:00pm	Section 28, poster board 4	Poster Session	Clonal Heterogeneity and Evolution	Reconstructing the evolutionary history of metastatic cancers
Cigall Kadoch	Ludwig Harvard	1:00pm - 2:45pm	New Orleans Theater A, Morial Convention Center	Major Symposium	Transcriptional Control in Cancer	Mammalian SWI/SNF (BAF) complex structure and function in human cancer
Anna Dembo,* Geoffrey Greene**	Ludwig Chicago	1:00pm - 5:00pm	Section 1, poster board 6	Poster Session	Molecular Endocrinology of Hormone-dependent Malignancies	ER-positive breast cancer prevention with the use of hormone replacement therapy
Jedd Wolchok	Ludwig MSK	1:00pm - 5:00pm	Section 27, poster board 21	Poster Session	Therapeutic Antibodies and Vaccines	1:00pm - 5:00pm: Pilot study of DNA microseeding to activate immune rejection of canine melanoma
Sridhar Ramaswamy	Ludwig Harvard	3:00pm - 5:00pm	Room 393, Morial Convention Center	Minisymposium	Epigenetic Alterations in Cancer	3:20pm - 3:35pm: Loss of SIRT6 reactivates the oncofetal RNA-binding protein Lin28b to drive pancreatic cancer
Robert Nakayama,* Robert Williams, Seth Cassel, Mingxiang Teng, Rafael Irizarry, George Demetri, Cigall Kadoch**	Ludwig Harvard	3:00pm - 5:00pm	Room 393, Morial Convention Center	Minisymposium	Epigenetic Alterations in Cancer	3:50pm - 4:05pm: Genome-wide mistargeting of oncogenic SWI/SNF(BAF) complexes in SMARCB1(BAF47)-deficient sarcomas
Crystal Mackall	Ludwig Stanford	3:00pm - 5:00pm	New Orleans Theater B, Morial Convention Center	Minisymposium	Immunotherapy Trial Results and Correlates	3:05pm - 3:20pm: Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Ralph Weichselbaum	Ludwig Chicago	5:00pm - 7:00pm	Grand Salon A, Hilton New Orleans Riverside	Town Meeting	AACR Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception	Invited speaker			
Kornelia Polyak (Chairperson)	Ludwig Harvard	5:00pm - 6:30pm	New Orleans Theater C, Morial Convention Center	Forum	Should Tumor Heterogeneity Guide Therapy?	Chairperson			
	TUESDAY, APRIL 19								
Jedd Wolchok	Ludwig MSK	7:00am - 8:00am	Room 393, Morial Convention Center	Meet-the-Expert Session	Cancer Immunotherapy: Of Mice and Men (and Dogs)	Invited speaker			
Crystal Mackall	Ludwig Stanford	7:00am - 8:00am	Room 271, Morial Convention Center	Meet-the-Expert Session	Immunotherapy for Childhood Malignancies	Invited speaker			
Michael Hemann	Ludwig MIT	7:00am - 8:00am	Room 354, Morial Convention Center	Meet-the-Expert Session	Mouse Models to Define Mechanisms of Drug Resistance	Invited speaker			
Joan Brugge	Ludwig Harvard	8:00am - 12:00pm	Section 2, poster board 24	Poster Session	Cell Cycle Control and Checkpoints	Regulation of cytokinesis by polo-like kinase 4			
Wenxin Zheng,* Kinga Skowron, Ainhoa Arina, Hua Liang, Ralph Weichselbaum**	Ludwig Chicago	8:00am -12:00pm	Section 12	Late-Breaking Research: Clinical Research 2 / Endocrinology	Late-Breaking Poster Session	Radiotherapy sensitizes pancreatic cancer to immunotherapy by promoting T cell infiltration			
Taha Merghoub, Daniel Hirschhorn-Cymerman, Gerd Ritter, Jedd Wolchok	Ludwig MSK; Ludwig New York	8:00am - 12:00pm	Section 25, poster board 1	Poster Session	Immune Checkpoints 2	INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells			
Sean Fanning, Geoffrey Greene	Ludwig Chicago	8:00am - 12:00pm	Section 20, poster board 17	Poster Session	Structural and Chemical Biology	Stapled peptide inhibitors of the estrogen receptor/steroid receptor coactivator interaction			
Yevgenia Khodor,* Daisy Riquelme, Frank Gertler, Christopher Burge**	Ludwig MIT	8:00am - 12:00pm	Section 8, poster board 9	Poster Session	Transcriptional Regulation and Gene Expression in Human Malignancies	Genes associated with neuronal development, including splicing regulatory factors, increase in expression across epithelial-mesenchymal transition			
Taha Merghoub, Gerd Ritter, Jedd Wolchok	Ludwig MSK; Ludwig New York	8:00am -12:00pm	Section 25, poster board 1	Poster Session	Immune Checkpoints 2	INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells			
Taha Merghoub, Sadna Budha, Roberta Zappasodi, Gerd Ritter, Jedd Wolchok	Ludwig MSK; Ludwig New York	8:00am -12:00pm	Section 25, poster board 17	Poster Session	Immune Checkpoints 3	A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR			
Ralph Weichselbaum	Ludwig Chicago	8:00am - 12:00pm	Section 18, poster board 3	Poster Session	Preclinical Radiotherapeutics	Survivin-mediated radio-sensitization response in p53 mutant tumor cells			

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Sushama Varma, Robert Sweeney, Matt van de Rijn	Ludwig Stanford	8:00am - 12:00pm	Section 23, poster board 19	Poster Session	Molecular Classification and Genomic Applications	Tumor associated macrophages in undifferentiated uterine sarcoma: association with angiogenesis and therapeutic implications
Alexander Lesokhin, Alexandra Snyder	Ludwig MSK	10:30am -12:15pm	Room 391, Morial Convention Center	Clinical Trials Plenary Session	Immuno-oncology Clinical Trials II	A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Anthony Letai**	Ludwig Harvard	1:00pm - 5:00pm	Section 2, poster board 1	Poster Session	Cell Death 1	Rational combination of targeted agents and BH3 mimetics to improve cancer treatment
Kornelia Polyak (Chairperson)	Ludwig Harvard	1:00pm - 2:45pm	New Orleans Theater B, Morial Convention Center	Major Symposium	Tumor Evolution Within the Host Microenvironment	1:40pm - 2:05pm: Immune-related changes in breast tumor evolution
Joan Brugge	Ludwig Harvard	1:00pm - 2:45pm	New Orleans Theater B, Morial Convention Center	Major Symposium	Tumor Evolution Within the Host Microenvironment	1:10pm - 1:35pm: Analysis of clonal populations derived from breast and ovarian tumors
Keehoon Jung, Takahiro Heishi, Andy Yun, Timothy Padera, Rakesh Jain, Dai Fukumura	Ludwig Harvard	1:00pm - 5:00pm	Section 33, poster board 3	Poster Session	Molecular and Cellular Imaging of Cancer 1	Targeting the immune microenvironment to improve colorectal cancer anti-angiogenic therapy
Elisabeth Bond, Gareth Bond	Ludwig Oxford	1:00pm - 5:00pm	Section 9, poster board 18	Poster Session	Tumor Suppressors: TP53 Pathway	Association of the G/G-SNP309 variant in the mdm2 gene with earlier tumor onset in female renal cell carcinoma patients
Ioannis Zervantonakis, Joan Brugge**	Ludwig Harvard	1:00pm - 5:00pm	Section 19, poster board 5	Poster Session	Targeting Protein Kinases, Death Pathways, and the Tumor Microenvironment	Design of effective combination therapies for high- grade serous ovarian cancer using patient- derived xenograft models
Stephen Hodi	Ludwig Harvard	1:00pm - 5:00pm	Section 10	Late-Breaking Poster Session	Late-Breaking Research: Tumor Biology 3	Landscape of tumor-infiltrating T-cell repertoire of human cancers
Stephen Hodi	Ludwig Harvard	1:00pm - 5:00pm	Section 27, poster board 10	Poster Session	Mechanisms and Applications of Immune-based Therapies	Recurrent gains of CD274 (PD-L1) and PDCD1LG2 (PD-L2) provide a genetic basis for PD-1 ligand expression in a subset of solid tumors
Jens-Peter Volkmer, Kevin Kao, Aditi Bellary, Irv Weissman	Ludwig Stanford	1:00pm - 5:00pm	Section 26, poster board 10	Poster Session	Immune Modulation from Non- Immunotherapy: Preclinical	The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy
Stephen Kron	Ludwig Chicago	1:00pm - 5:00pm	Section 23, poster board 9	Poster Session	Circulating Biomarkers 3 / Immune Biomarkers	Rapid 5-marker multiplex phenotyping of breast cancer subtypes & tumor-infiltrating leukocytes "in situ" in FFPE sections
Margaret Hoang, Aviv Regev (Chairperson)	Ludwig Johns Hopkins; Ludwig MIT	1:00pm - 2:45pm	Room 354, Morial Convention Center	Major Symposium	SY28. Population Genetics Meets Single Cell Analysis	Accumulation of somatic mutations in normal and cancerous tissues with age
Matthias Ernst	Ludwig Melbourne	1:00pm - 5:00pm	Section 28, poster board 14	Poster Session	Chemical and Viral Carcinogenesis	DNA damage and tumour burden in mouse colon is increased in response to carcinogen exposure after induction of chronic inflammation - a more disease relevant model of colitis-associated colorectal cancer?

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Bjarne Bartlett, Maria Popoli,	Ludida Jahan Hanti	4:00: 5:00:	04: 004 14-7	Dantar Caraina	Circulating Biomarkers 3 /	Optimized plasma collection procedures for liquid
Luis Diaz**	Ludwig Johns Hopkins	1:00pm - 5:00pm	Section 23: poster board 17	Poster Session	Immune Biomarkers	biopsy analyses in cancer
Stephen Hodi**	Ludwig Harvard	3:00pm - 5:00pm	Room 343, Morial Convention Center	Clinical Trials Minisymposium	Early Clinical Trials Evaluating Cell-based, Checkpoint Inhibitors, and Novel Immunotherapeutics	3:30pm - 3:45pm: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)
Aviv Regev, Levi Garraway**	Ludwig MIT; Ludwig Harvard	3:00pm - 5:00pm	New Orleans Theater A, Morial Convention Center	Minisymposium	New "Cool Tools" for Cancer Discovery	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-sequencing
Levi Garraway, Calvin Kuo	Ludwig Harvard; Ludwig Stanford	3:00pm - 5:00pm	Room 265, Morial Convention Center	Minisymposium	Genomic Alterations and Their Functional Consequences	Accelerating prediction of tumor vulnerabilities using next-generation cancer models
Joan Brugge**	Ludwig Harvard	3:00pm - 5:00pm	New Orleans Theater B, Morial Convention Center	Minisymposium	Identifying Targets and Combinations through Novel Approaches	Neutralization of BCL2/XL enhances the cytotoxicity of T-DM1 in vivo
Anthony Letai	Ludwig Harvard	5:00pm - 6:30pm	Room 293, Morial Convention Center	Forum	Genotype Versus Phenotype for Patient Selection	Invited speaker
			WEDNESDAY, A	PRIL 20		
Tyler Jacks	Ludwig MIT	7:00am - 8:00am	Room 393, Morial Convention Center	Meet-the-Expert Session	Engineering the Cancer Genome	Invited speaker
Zohreh Amoozgar,* Jonas Kloepper, Meenal Datta, Keehoon Jung	Ludwig Harvard	8:00am - 12:00pm	Section 11	Late-Breaking Poster Session	Late-Breaking Research: Tumor Biology 4	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Jonas Kloepper,* Zohreh Amoozgar, Meenal Datta, Keehoon Jung, Dai Fukumura, Rakesh Jain**	Ludwig Harvard	8:00am - 12:00pm	Section 11	Late-Breaking Poster Session	Late-Breaking Research: Tumor Biology 4	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
	Pfizer; iTeos Therapeutics: research conducted with Ludwig licensed technology	8:00am - 12:00pm	Section 22, poster board 4	Poster Session	Immune Modulating Agents 2	PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors
James Bradner	Ludwig Harvard	8:00am - 12:00pm	Section 16, poster board 24	Poster Session	Epigenetic Agents	BET bromodomain degradation as a therapeutic strategy in drug-resistant multiple myeloma
Gerd Ritter, Taha Merghoub, Jedd Wolchok	Ludwig New York; Ludwig MSK	8:00am - 12:00pm	Section 26; poster board 29	Poster Session	Immune Modulation from Non- Immunotherapy and Antibodies: Clinical	AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
Aviv Regev	Ludwig MIT	8:00am - 12:00pm	Section 37, poster board 3	Poster Session	New Bioinformatic Tools, Databases, Portals, and Data Resources	Fast and accurate fusion transcript detection using the Trinity Cancer Transcriptome Analysis Toolkit

^{*}denotes scientist is lead author

^{**}denotes scientist is senior author

Ludwig Presence at 2016 AACR Annual Meeting

James Bradner	Ludwig Harvard	8:00am - 12:00pm	Section 16, poster board 24	Poster Session	Epigenetic Agents	BET bromodomain degradation as a therapeutic strategy in drug-resistant multiple myeloma
Gerd Ritter, Taha Merghoub, Jedd Wolchok	Ludwig New York; Ludwig MSK	8:00am - 12:00pm	Section 26, poster board 29	Poster Session	Immune Modulation from Non- Immunotherapy and Antibodies: Clinical	AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
Stephen Hodi	Ludwig Harvard	8:00am - 12:00pm	Section 26, poster board 13	Poster Session	Immune Modulation from Non- Immunotherapy and Antibodies: Clinical	Toxicity profile of contemporaneous PD-1 inhibitor immunotherapy and radiotherapy
Sean Fanning,* David Hosfield, Geoffrey Greene**	Ludwig Chicago	8:00am - 12:00pm	Section 21, poster board 19	Poster Session	Drug Design	Bazedoxifene inhibits ESR1 somatic mutants with improved potency compared to tamoxifene and raloxifene
Frank Gertler**	Ludwig MIT	8:00am - 12:00pm	Section 29, poster board 3	Poster Session	Cellular and Molecular Dynamics of Cancer Migration and Invasion	Mena at the nexus of chemotaxis and haptotaxis during tumor progression
Luis Diaz	Ludwig Johns Hopkins	7:45am - 9:30am	La Nouvelle Orleans Ballroom, Morial Convention Center	Plenary session	Detection and Monitoring of Pre-Malignant Disease and Therapeutic Response	7:45am - 8:10am: Liquid biopsies and the early diagnosis of cancer
Anthony Letai (Chairperson)	Ludwig Harvard	10:15am - 12:00pm	Room 343, Morial Convention Center	Major Symposium	Precision Cancer Medicine Using Functional Testing	10:25am - 10:50am: Precision cancer medicine using BH3 profiling
Alexander Rudensky (Chairperson)	Ludwig MSK	10:15am -12:00pm	New Orleans Theater B, Morial Convention Center	Major Symposium	Function of T Cells and Their Therapeutic Application in Cancer	10:55am - 11:20am: Function of regulatory T cells in cancer

**denotes scientist is senior author